SHARES in Viralytics have jumped by 10 per cent after a significant number of patients responded well to a cancer therapy the company is developing.
The company's shares gained 3.5 cents to 38 cents.
Viralytics said a phase two clinical trial of its treatment Cavatak on late-stage melanoma patients had already achieved its main goal, even though patients were still being recruited for the study.
The trial, across 10 sites in the United States, is investigating the safety and efficacy of Cavatak on 54 evaluable patients.
The aim is to have 10 out of 54 patients go six months after their first dose of Cavatak without the cancer worsening.
Viralytics on Wednesday said 10 patients had already achieved the goal, with only 30 evaluated.
"Given the excellent progress achieved to date and the encouraging feedback from key opinion leaders in the melanoma field, we also believe it is now timely to consider the design of a randomised study in melanoma patients," Viralytics chief executive Dr Malcolm McColl said.
Currently 44 patients are enrolled in the trial. Full enrolment is expected by the end of the year.
Cavatak is a natural, genetically unaltered virus that often causes no symptoms in humans, but can induce mild upper respiratory symptoms similar to that of the common cold viruses.
Its therapeutic action results through its interaction with the ICAM-1 receptor which is present in abundance on the surface of many cancer cells.
Anda sedang membaca artikel tentang
Viralytics shares up 14 per cent
Dengan url
http://laptoptua.blogspot.com/2013/09/viralytics-shares-up-14-per-cent.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Viralytics shares up 14 per cent
namun jangan lupa untuk meletakkan link
Viralytics shares up 14 per cent
sebagai sumbernya
0 komentar:
Posting Komentar